Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. Sauta E, et al. Among authors: voso mt. J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930857 Free PMC article.
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Voso MT, et al. Clin Cancer Res. 2009 Aug 1;15(15):5002-7. doi: 10.1158/1078-0432.CCR-09-0494. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638460 Free article. Clinical Trial.
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Musto P, et al. Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. Cancer. 2010. PMID: 20151429 Free article.
Outcome of therapy-related myeloid neoplasms treated with azacitidine.
Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT. Fianchi L, et al. Among authors: voso mt. J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44. J Hematol Oncol. 2012. PMID: 22853048 Free PMC article.
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A. Voso MT, et al. J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796988
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.
Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Efficace F, et al. Among authors: voso mt. Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557. Ann Oncol. 2014. PMID: 24478321 Free article.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Among authors: voso mt. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
305 results